Quest Diagnostics (NYSE:DGX) Releases FY 2025 Earnings Guidance

Quest Diagnostics (NYSE:DGX) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 9.550-9.800 for the period, compared to the consensus earnings per share estimate of 9.710. The company issued revenue guidance of $10.7 billion-$10.9 billion, compared to the consensus revenue estimate of $10.8 billion.

Analyst Ratings Changes

Several equities research analysts have issued reports on DGX shares. Robert W. Baird boosted their price target on shares of Quest Diagnostics from $190.00 to $191.00 and gave the company an “outperform” rating in a report on Thursday. UBS Group upped their target price on shares of Quest Diagnostics from $166.00 to $170.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Jefferies Financial Group restated a “buy” rating and set a $185.00 price target (up previously from $175.00) on shares of Quest Diagnostics in a research note on Tuesday, December 10th. JPMorgan Chase & Co. lifted their price objective on Quest Diagnostics from $173.00 to $180.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Finally, Truist Financial increased their target price on Quest Diagnostics from $172.00 to $182.00 and gave the stock a “hold” rating in a report on Friday, January 31st. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $178.38.

Quest Diagnostics Price Performance

Shares of DGX stock opened at $166.25 on Friday. Quest Diagnostics has a 52 week low of $125.42 and a 52 week high of $178.87. The stock has a market capitalization of $18.45 billion, a PE ratio of 21.62, a PEG ratio of 2.16 and a beta of 0.92. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.02 and a current ratio of 1.10. The stock’s fifty day moving average is $164.88 and its 200-day moving average is $158.53.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $2.23 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.04. Quest Diagnostics had a net margin of 8.80% and a return on equity of 15.07%. Equities research analysts expect that Quest Diagnostics will post 9.7 EPS for the current fiscal year.

Quest Diagnostics Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, April 21st. Investors of record on Monday, April 7th will be issued a $0.80 dividend. The ex-dividend date is Monday, April 7th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.92%. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.75. Quest Diagnostics’s dividend payout ratio (DPR) is currently 41.61%.

Insiders Place Their Bets

In other Quest Diagnostics news, Director Vicky B. Gregg sold 1,250 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $164.57, for a total value of $205,712.50. Following the transaction, the director now directly owns 16,867 shares of the company’s stock, valued at approximately $2,775,802.19. This trade represents a 6.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mark E. Delaney sold 403 shares of the company’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $164.30, for a total transaction of $66,212.90. Following the sale, the senior vice president now owns 4,624 shares of the company’s stock, valued at $759,723.20. The trade was a 8.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,157 shares of company stock valued at $2,423,755. 0.79% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Quest Diagnostics

A hedge fund recently bought a new stake in Quest Diagnostics stock. Brighton Jones LLC acquired a new stake in Quest Diagnostics Incorporated (NYSE:DGX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,144 shares of the medical research company’s stock, valued at approximately $323,000. 88.06% of the stock is owned by institutional investors and hedge funds.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.